References
- Arlock P., Gullberg B., Olsson S.-O.R. Cardiac electrophysiology of four neuroleptics: melperone, haloperidol, thioridazine and chlorpromazine. Archs Pharmac 1978; 304: 27
- Brorson L., Olsson B. Right atrial monophasic action potential in healthy males. Studies during spontaneous sinus rhythm and atrial pacing. Acta med. scand 1976; 199: 433
- Christensen J. A., Hernestam S., Lassen J. B., Sterner N. Pharmacological and toxicological studies on y-(4-methylpiperidino)-p-fluorobutyro-phenone (FG5111)—a new neuroleptic agent. Acta pharmac. (Kbh) 1965; 23: 109
- Dreifus L. S., Ogawa S. Quality of the ideal anti-arrhythmic drug. Am. J. Cardiol 1977; 39: 466
- Olsson S. B., Cotoi S., Varnauskas E. Mono-phasic action potential and sinus rhythm stability after conversion of atrial fibrillation. Acta. med. scand 1971; 190: 381
- Oversen L., Møgelvang J. C., Personal communication
- Petersen E. Antiarrhythmic effect of a nauroleptic compound melperone. Ouabainantagonism, 7th European Congress of Cardiology. Amsterdam June, 1976; 20–25, Abstract book 11, p. 342, 1976
- Petersen E. Experimental antiarrhythmic properties of melperone, a neuroleptic butyrophenone. Acta pharmac. tox 1978; 42: 388
- Refsum H., Passwal M., Olsson S.-O. Comparison of the electrophysiological effects of two neuroleptics, melperone and thioridazine, on isolated rat atria. Eur. J. Pharmac 1978; 49: 285
- Platou E. S., Refsum H., Amlie J. P., Landmark K. Anti-arrhythmic action of melperone in the dog heart in situ. Acta pharmac. tox 1979; 44: 158
- Rosenbaum M. B., Chiale P. A., Halpern M. S., Nau G. J., Przybylski J., Levi R. J., Lazzari J. O., Elizari M. V. Clinical efficacy of amiodarone as an antiarrhythmic agent. Am. J. Cardiol 1976; 38: 934
- Vaughan Williams E. M. Classification of antiarrhythmic drugs. Symposium on Cardiac Arrhythmias, E. Sandoe, E. Flensted-Jensen, K. H. Olesen. AB Astra, SödertäljeSweden 1970; 449
- Zipes D. P., Troup P. J. New antiarrhythmic agents. Am. J. Cardiol 1978; 41: 1005